1 Correction to: Drugs - Real World Outcomes (2020). https://doi.org/10.1007/s40801-020-00183-x

Changes within text are indicated in bold.


Page 1, Abstract, Results section: The following sentence, which previously read:


“The oral treprostinil cohort had 66.9% lower total PAH-related healthcare costs (mean difference − $75,183; 95% confidence interval [CI] − 102,584 to − 49,771) and 70.6% lower PAH-related pharmacy costs (mean difference − $76,439; 95% CI − 104,512 to − 51,458) than the selexipag cohort, with similar differences in all-cause healthcare and pharmacy costs.”


should read:


“The selexipag cohort had 66.9% higher total PAH-related healthcare costs (mean difference $75,183; 95% confidence interval [CI] 49,771 to 102,584) and 70.6% higher PAH-related pharmacy costs (mean difference $76,439; 95% CI 51,458 to 104,512) than the oral treprostinil cohort, with similar differences in all-cause healthcare and pharmacy costs.”


Page 3, Methods, Section 2.2, top of column 2, lines 1–2: The following sentence that previously read:


“PAH-related HCRU was identified using PH diagnosis codes in any position.”


should read:


“PAH-related HCRU was identified using PH diagnosis codes in the primary diagnosis code field.”


Page 4, Results section, column 1, paragraph 1, lines 18–22: The following sentence that previously read:


“There was a 10% difference in the proportion of patients who underwent RHC in the 6 months prior to being prescribed oral prostacyclin, although this difference did not meet statistical significance (47.7 vs. 36.5% for oral treprostinil and selexipag, respectively; p = 0.07).”


should read:


“There was an 11.2% absolute difference in the proportion of patients who underwent RHC in the 6 months prior to being prescribed oral prostacyclin, although this difference did not meet statistical significance (47.7 vs. 36.5% for oral treprostinil and selexipag, respectively; p = 0.07).”


Page 6, Sect. 3.3 Healthcare Resource Use and Costs, column 1, paragraph 2, lines 7–10: The following sentence that previously read:


“Notably, a higher proportion of patients in the oral treprostinil cohort received RHC during the post-index period compared with the selexipag cohort (13.2 vs. 5.6%, respectively; p = 0.039).”


should read:


“Notably, a higher proportion of patients in the oral treprostinil cohort received RHC during the post-index period compared with the selexipag cohort (13.1 vs. 5.6%, respectively; p = 0.039).”


Page 6, Sect. 3.3 Healthcare Resource Use and Costs, column 2, last paragraph: The following sentence that previously read:


“After adjustment for covariates, treatment with oral treprostinil was associated with 51.4% lower total all-cause healthcare costs than treatment with selexipag(difference in mean − $73,680; 95% confidence interval [CI] − 103,702 to − 43,963) (Fig. 4). This difference in all-cause healthcare costs was largely driven by all-cause pharmacy costs, which were 68.2% lower in patients being treated with oral treprostinil than in those being treated with selexipag(difference in mean − $77,654; 95% CI − 105,392 to − 52,118). Treatment with oral treprostinil was associated with 66.9% lower total PAH-related healthcare costs compared with being treated with selexipag(difference in mean − $75,183; 95% CI − 102,584 to − 49,771). Differences in PAH-related healthcare costs were largely driven by PAH-related pharmacy costs, which were 70.62% lower in patients treated with oral treprostinil than in those treated with selexipag(difference in mean − $76,439; 95% CI − 104,512 to − 51,458).”


should read:


“After adjustment for covariates, treatment with selexipag was associated with 51.4% higher total all-cause healthcare costs than treatment with oral treprostinil(difference in mean $73,680; 95% confidence interval [CI] $43,963 to $103,702) (Fig. 4). This difference in all-cause healthcare costs was largely driven by all-cause pharmacy costs, which were 68.2% higher in patients being treated with selexipag than in those being treated with oral treprostinil(difference in mean $77,654; 95% CI $52,118 to $105,392). Treatment with selexipag was associated with 66.9% higher total PAH-related healthcare costs compared with being treated with oral treprostinil(difference in mean $75,183; 95% CI $49,771 to $102,584). Differences in PAH-related healthcare costs were largely driven by PAH-related pharmacy costs, which were 70.62% higher in patients treated with selexipag than in those treated with oral treprostinil(difference in mean $76,439; 95% CI $51,458 to $104,512).”


Page 7, Table 2, ‘Healthcare resource utilization during the post-index period’: The cell entry in the ‘p value’ column, ‘Inpatient visits’ row, which was previously blank, should read “0.073”


Page 8, Discussion section, column 1, first paragraph, lines 9–19: The following sentence that previously read:


“Results suggest that treatment with oral treprostinil was associated with 51.4% lower total all-cause healthcare costs compared with treatment with selexipag, and this was largely driven by all-cause pharmacy costs, which were 68.2% lower in patients treated with oral treprostinil than in those treated with selexipag. Treatment with oral treprostinil was associated with 66.9% lower total PAH-related healthcare costs compared with treatment with selexipag, again largely driven by 70.6% lower PAH-related pharmacy costs in patients being treated with oral treprostinil than in those being treated with selexipag.”


should read:


“Results suggest that treatment with selexipag was associated with 51.4% higher total all-cause healthcare costs compared with treatment with oral treprostinil, and this was largely driven by all-cause pharmacy costs, which were 68.2% higher in patients treated with selexipag than in those treated with oral treprostinil. Treatment with selexipag was associated with 66.9% higher total PAH-related healthcare costs compared with treatment with oral treprostinil, again largely driven by 70.6% higher PAH-related pharmacy costs in patients being treated with selexipag than in those being treated with oral treprostinil.”